Halozyme Therapeutics, Inc. (HALO), Viropharma Inc (VPHM): Three Horrendous Health-Care Stocks This Week

The company upped its full-year revenue guidance to $103 million-$105 million. Cadence previously gave 2013 guidance of $97 million-$103 million.

Most likely to improve

Each week, I attempt to identify which of the week’s worst-performing health-care stocks is most likely to rebound. This time around, though, I’ll have to waffle on that pick. I think that any of these three stocks could easily make a solid comeback.

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s rHuPH20 has been part of a lot of clinical trials without alarming safety issues. Unless there’s more to this story than we know right now, the stock should bounce back. Sunesis doesn’t have the track record with vosaroxin that Halozyme Therapeutics, Inc. (NASDAQ:HALO) has with rHuPH20, but worries stemming from the halted Cardiff University study could ultimately prove to present no issues for the company’s study.

Cadence’s earnings miss wasn’t good news, but Ofirmev’s growth trajectory is. I suspect the company can get back into the winner’s column in the coming quarters.

Granted, further issues could derail any or all of these stocks. For now, though, I pick all three as most likely to improve.

The article 3 Horrendous Health-Care Stocks This Week originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.